feed,title,long_url,short_url
BioRxiv,Predicting the antigenic evolution of SARS-COV-2 with deep learning,https://biorxiv.org/cgi/content/short/2022.06.23.497375v1?rss=1,https://bit.ly/3nhaEDE
BioRxiv,"A cell-based, spike protein binding assay highlights differences in antibody neutralising capacity for SARS-CoV-2 variants",https://biorxiv.org/cgi/content/short/2022.06.24.496409v1?rss=1,https://bit.ly/3OJSPJb
BioRxiv,In Vitro Evaluation and Mitigation of Niclosamide Liabilities as a COVID-19 Treatment,https://biorxiv.org/cgi/content/short/2022.06.24.497526v1?rss=1,https://bit.ly/3HTeImR
BioRxiv,DESIGN OF A CHIMERIC ACE-2/Fc-SILENT FUSION PROTEIN WITH ULTRAHIGH AFFINITY AND NEUTRALIZING CAPACITY FOR SARS-CoV-2 VARIANTS,https://biorxiv.org/cgi/content/short/2022.06.23.497326v1?rss=1,https://bit.ly/3OCHLxk
BioRxiv,Investigating the mutations in the SARS-CoV-2 proteins among European countries,https://biorxiv.org/cgi/content/short/2022.06.23.497239v1?rss=1,https://bit.ly/3xWkf7G
BioRxiv,The Functional Landscape of SARS-CoV-2 3CL Protease,https://biorxiv.org/cgi/content/short/2022.06.23.497404v1?rss=1,https://bit.ly/3xLDWio
BioRxiv,Monitoring SARS-CoV-2 infection using a double reporter-expressing virus,https://biorxiv.org/cgi/content/short/2022.06.23.497376v1?rss=1,https://bit.ly/3brqIjE
